Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1970 1
1974 1
1975 5
1976 2
1977 5
1978 2
1979 2
1980 3
1981 8
1982 4
1983 15
1984 13
1985 14
1986 18
1987 25
1988 16
1989 20
1990 19
1991 31
1992 21
1993 23
1994 24
1995 21
1996 29
1997 29
1998 12
1999 18
2000 23
2001 17
2002 22
2003 29
2004 35
2005 27
2006 23
2007 19
2008 14
2009 12
2010 9
2011 15
2012 11
2013 13
2014 5
2015 6
2016 2
2017 2
2018 2
2019 6
2020 3
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

666 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Winquist E, et al. J Urol. 2004 Feb;171(2 Pt 1):561-9. doi: 10.1097/01.ju.0000090967.08622.33. J Urol. 2004. PMID: 14713760 Review.
MATERIALS AND METHODS: A systematic review and meta-analysis were performed of all known randomized controlled trials (RCTs) of neoadjuvant chemotherapy for stages II and III TCC conducted between 1984 and 2002. ...
MATERIALS AND METHODS: A systematic review and meta-analysis were performed of all known randomized controlled trials (RCTs) of neoad …
Carcinoma in situ.
Lamm DL. Lamm DL. Urol Clin North Am. 1992 Aug;19(3):499-508. Urol Clin North Am. 1992. PMID: 1636234 Review.
Carcinoma in situ is a high-grade and aggressive manifestation of transitional-cell carcinoma of the bladder that has a highly variable course. ...While it is recommended that patients be offered the option of radical cystectomy, data do …
Carcinoma in situ is a high-grade and aggressive manifestation of transitional-cell carcinoma of the b …
Transurethral Resection of the Bladder Tumour as a Treatment Method in Children with Transitional Cell Carcinoma of the Bladder--Analysis of Our Material and Literature Review.
Apoznański W, Rysiakiewicz J, Polok M, Rysiakiewicz K, Siekanowicz P, Hilger T, Zagierski J, Hilger M, Nowak I, Kolęda P, Szydełko T. Apoznański W, et al. Adv Clin Exp Med. 2015 May-Jun;24(3):505-9. doi: 10.17219/acem/36600. Adv Clin Exp Med. 2015. PMID: 26467141 Free article. Review.
In all other cases complete remission was achieved. CONCLUSIONS: Transitional cell carcinoma of the bladder in children is usually benign and endoscopic treatment (TUR-BT) seems to be the treatment of choice. ...
In all other cases complete remission was achieved. CONCLUSIONS: Transitional cell carcinoma of the bl …
Collagen XI alpha 1 chain, a potential therapeutic target for cancer.
Liu Z, Lai J, Jiang H, Ma C, Huang H. Liu Z, et al. FASEB J. 2021 Jun;35(6):e21603. doi: 10.1096/fj.202100054RR. FASEB J. 2021. PMID: 33999448 Review.
Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) has been found to be upregulated in a variety of cancers including ovarian cancer, breast cancer, thyroid cancer, pancreatic cancer, non-small-cell lung cancer, and transitional …
Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) has been found to be upregulated in a variety o …
The integration of chemotherapy and surgery for bladder cancer.
Galsky MD, Herr HW, Bajorin DE. Galsky MD, et al. J Natl Compr Canc Netw. 2005 Jan;3(1):45-51. doi: 10.6004/jnccn.2005.0003. J Natl Compr Canc Netw. 2005. PMID: 19813322 Review.
Despite surgery with curative intent, approximately 50% of patients with muscle-invasive transitional cell carcinoma of the bladder will develop distant metastases and succumb to their disease. ...
Despite surgery with curative intent, approximately 50% of patients with muscle-invasive transitional cell carcinoma …
EO9 (Apaziquone): from the clinic to the laboratory and back again.
Phillips RM, Hendriks HR, Peters GJ; EORTC-Pharmacology and Molecular Mechanism Group. Phillips RM, et al. Br J Pharmacol. 2013 Jan;168(1):11-8. doi: 10.1111/j.1476-5381.2012.01996.x. Br J Pharmacol. 2013. PMID: 22509926 Free PMC article. Review.
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic eli …
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity …
Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS, Torti FM. Miller RS, et al. Cancer Chemother Pharmacol. 1992;30 Suppl:S99-110. doi: 10.1007/BF00686953. Cancer Chemother Pharmacol. 1992. PMID: 1394829 Review.
A number of single agents and multidrug combinations are useful in the therapy of advanced transitional-cell carcinoma of the bladder. Phase II studies have identified cisplatin, Adriamycin (doxorubicin), methotrexate, and vinblastine as …
A number of single agents and multidrug combinations are useful in the therapy of advanced transitional-cell carcinoma …
Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire.
Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J, Schned A. Karagas MR, et al. Cancer Causes Control. 2004 Jun;15(5):465-72. doi: 10.1023/B:CACO.0000036452.55199.a3. Cancer Causes Control. 2004. PMID: 15286466
To examine the effects of lower levels of arsenic exposure on bladder cancer incidence, we conducted a case-control study in New Hampshire, USA where levels above 10 micro/l are commonly found in private wells. METHODS: We studied 383 cases of transitional cell c …
To examine the effects of lower levels of arsenic exposure on bladder cancer incidence, we conducted a case-control study in New Hampshire, …
Virus therapy for bladder cancer.
Burke J. Burke J. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):99-102. doi: 10.1016/j.cytogfr.2010.02.003. Epub 2010 Apr 9. Cytokine Growth Factor Rev. 2010. PMID: 20382064 Review.
Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder. Based on ease of administration, limited systemic dissemination, and the demonstrated activity of …
Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma …
666 results